About us

Energenesis Biomedical Announces Positive Phase I Results for ENERGI-F705PD, a Potential Disease-Modifying Treatment for Parkinson’s Disease

Energenesis Biomedical and Medvisis Switzerland AG Sign MOU for F703DFU Commercialization in Switzerland

Energenesis Biomedical and Phison Sign MOU to Advance AI-Driven Drug Development

Energenesis Biomedical Co., Ltd. has signed a Memorandum of Understanding (MOU) with DEBRA Research gGmbH to collaborate on the development of F703EB.

Energenesis Biomedical has received CRO notification that its Phase I IND application for "ENERGI-F705PD," an oral Parkinson's treatment, has been conditionally approved by the Ministry of Health and Welfare to begin clinical trials.

Energenesis Biomedical Signs MOU with Taiwan Tanabe Seiyaku Co., Ltd., a subsidiary of Mitsubishi Tanabe Pharma Corporation, Japan, for the Commercialization Rights of F703DFU in Taiwan and Southeast Asia (ASEAN)

EB Announces Exclusive Licensing Agreement with PBI Portugal Unipessoal Lda., a wholly owned subsidiary of the German group Pharma Bavaria International

EB Receives Notification from CRO Regarding IND Submission to TFDA for Phase I Clinical Trial of ENERGI-F705PD, an Oral Treatment for Parkinson's Disease.

EB's proprietary 'METHOD FOR TREATING EPIDERMO-LYSIS BULLOSA' has been granted patent approval by the Intellectual Property Office

Energenesis's Novel Diabetic Foot Ulcer Gel Wins Excellence Award in Innovation Technology at 2024 Taipei Biotech Awards